The PharmaTimes Communications Team of the year competition is now open for entry, with two new categories offering yet more opportunities for forward thinking agencies!
News
Only one week to go – BOOK NOW
The PharmaTimes International Clinical Researcher of the Year Awards Ceremony & Gala Dinner is to take place next Thursday (17 May) at the Millenium Gloucester Hotel in London’s Kensington.
Janssen’s Tremfya backed for NHS use
Janssen’s Tremfya has been recommended by NICE as a cost-effective treatment for plaque psoriasis.
Lilly buys ARMO BioSciences for $1.6 billion
Eli Lilly is buying ARMO BioSciences in a deal valued at around $1.6 billion, to ramp up its immune-oncology pipeline.
Scientists discover mutation that causes PARP inhibitor resistance
Scientists have made a major discovery having identified a mutation that gives cancer cells resistance to AstraZeneca’s Lynparza and other PARP inhibitors.
FDA advisors back approval of Akcea’s volanesorsen
Akcea Therapeutics’ volanesorsen has taken a step closer to becoming the first therapy on the US market for the ultra-rare rare lipid disorder familial chylomicronemia syndrome (FCS).
GP continuity of care is slipping, finds study
A study published in the British Journal of General Practice has found that it is becoming increasingly difficult for patients to get appointments with their GP of choice.
Testosterone replacement drug rejected by FDA
US regulators have rejected Lipocine’s Tlando, a testosterone replacement therapy for adult males with hypogonadism.
Roche’s Tecentriq/Cotellic study fails in colorectal cancer trial
Roche has revealed that a combination of Tecentriq and Cotellic tested in a late-stage trial failed to improve overall survival compared to regorafenib in patients with advanced metastatic colorectal cancer (CRC).
GSK’s chief financial officer to retire
GlaxoSmithKline has announced that its chief financial officer Simon Dingemans is to retire.
Gov’t suspends controversial NHS data sharing deal
The government has taken a u-turn on controversial data-sharing arrangements under which the NHS was able to hand over patient details to the Home Office for immigration tracking purposes.
Takeda to buy Shire for £46 billion
Takeda is moving ahead with its quest to acquire UK-listed Shire, after the latter approved an offer equating to around £46 billion.
EU regulators widen Lynparza’s reach
European regulators have approved a tablet formulation and new dosing regimen for AstraZeneca and MSD’s Lynparza to treat a wider range of patients with ovarian cancer.
NHS England moves to fast-track clinical trials
NHS England has unveiled new processes designed to fast track clinical trials undertaken across the NHS, and boost access for patients.
UK synthetic antibody firm raises £1.5m
A UK-based life sciences group developing synthetic alternatives to antibodies has raised investment of £1.5 million to help advance its business.
